|Year : 2021 | Volume
| Issue : 2 | Page : 195-200
Evaluation of breathing-adapted radiation therapy for right-sided early stage breast cancer patients
Selcuk Demiral, Omer Sager, Ferrat Dincoglan, Bora Uysal, Hakan Gamsiz, Yelda Elcim, Bahar Dirican, Murat Beyzadeoglu
Department of Radiation Oncology, Gulhane Medical Faculty, University of Health Sciences, Gn.TevfikSaglam Cad., Etlik, 06018, Kecioren, Ankara, Turkey
|Date of Submission||14-Feb-2019|
|Date of Decision||28-Apr-2019|
|Date of Acceptance||06-May-2019|
|Date of Web Publication||7-Jun-2021|
Department of Radiation Oncology, Gulhane Medical Faculty, University of Health Sciences, Gn.TevfikSaglam Cad., Etlik, 06018, Kecioren, Ankara
Source of Support: None, Conflict of Interest: None
Background: Adverse effects of breast irradiation have been an important concern given the increased survival of early stage breast cancer (ESBC) patients with more effective treatments. However, there is paucity of data on the utility of Active Breathing Control (ABC) technique for right-sided ESBC patients. In this study, we assessed the incorporation of ABC into adjuvant Radiation Therapy (RT) of right-sided ESBC patients and report our dosimetric results.
Methods: Thirty-six patients receiving whole breast irradiation followed by a sequential tumor bed boost were included in the study. All patients received field-in-field intensity modulated radiation therapy with incorporation of active breathing control-moderate deep inspiration breath-hold (ABC-mDIBH) after breast conserving surgery. Dose–volume parameters in both plans with and without ABC-mDIBH were compared using Mann-Whitney U test.
Results: Mean lung dose decreased from 7 Gy to 5.2 Gy (26% reduction) for the total lung (p < 0.001) and from 12.6 to 9.4 Gy (25% reduction) for the ipsilateral lung (p < 0.001). Mean dose decreased from 4.6 Gy to 1.7 Gy (58% reduction) for liver (p < 0.001) and 1.7 Gy to 1.4 Gy (16% reduction) for the heart (p < 0.001).
Conclusion: Our study revealed that incorporation of ABC-mDIBH into adjuvant RT of right-sided ESBC patients results in significantly improved critical organ sparing.
Keywords: Active breathing control, breast cancer, breast-conserving surgery, breath-hold, radiotherapy
Key Message: Incorporation of breathing adapted radiation therapy for radiotherapeutic management of right-sided early stage breast cancer patients significantly improved critical organ sparing in our study. This viable strategy may be utilized for improving the toxicity profile of radiation therapy for right-sided early stage breast cancer patients.
|How to cite this article:|
Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, Elcim Y, Dirican B, Beyzadeoglu M. Evaluation of breathing-adapted radiation therapy for right-sided early stage breast cancer patients. Indian J Cancer 2021;58:195-200
|How to cite this URL:|
Demiral S, Sager O, Dincoglan F, Uysal B, Gamsiz H, Elcim Y, Dirican B, Beyzadeoglu M. Evaluation of breathing-adapted radiation therapy for right-sided early stage breast cancer patients. Indian J Cancer [serial online] 2021 [cited 2021 Jun 23];58:195-200. Available from: https://www.indianjcancer.com/text.asp?2021/58/2/195/297012
| » Introduction|| |
Breast cancer remains to be a major health concern as the most frequently diagnosed cancer in women and a leading cause of cancer-related deaths in females worldwide.,, Radiation therapy (RT) plays a central role in breast cancer management with increased use of breast conserving therapy (BCT). While there is compelling evidence to justify the institution of RT after breast conserving surgery (BCS) to improve local control and survival, adverse effects of breast irradiation have been an important concern given the increased survival of early stage breast cancer (ESBC) patients with more effective treatments.,,
Several studies have focused on improving the toxicity profile of radiation delivery for patients with breast cancer using different RT approaches, and dosimetric benefits of breathing-adapted RT have been reported in the era of contemporary RT techniques.,,,,,,,,,,,,,
Among the several techniques used for improving the toxicity profile of radiation delivery for breast cancer patients, Active Breathing Control (ABC) system deserves utmost attention and has proved to be useful for left-sided breast cancer management particularly for cardiac sparing.,,,,,,,, However, there is scant data on the utility of ABC for right-sided breast cancer patients. In this study, we assessed the impact of ABC technique on lung, heart, and liver doses in right-sided ESBC radiotherapy and report our comparative dosimetric results.
| » Materials and Methods|| |
Between January 2018 and October 2018, 36 patients with right-sided ESBC (pT1-2N0M0) were included in the study. Patients were treated with whole breast irradiation (WBI) followed by a sequential tumor bed boost using active breathing control-moderate deep inspiration breath-hold (ABC-mDIBH) after BCS. Written informed consents of all patients were acquired prior to treatment with institutional tumor board approval at our tertiary cancer center, and the study was performed in compliance with the Declaration of Helsinki principles and its later amendments. RT was delivered at mDIBH by using the ABC system (ABC, Elekta, UK) for all patients. Patient, tumor, and treatment characteristics are summarized in [Table 1].
Before computed tomography (CT)-simulation, patients were trained for improving their compliance with the ABC system. Instructions about achieving reproducible mDIBH for precision RT and potential benefits of the ABC system were explained to the patients. Individual thresholds for mDIBH were determined and saved to be used for CT-simulation and treatment. The training session was completed after it was confirmed that the patients complied with breathing adapted RT procedure by achieving reproducible breath holding at moderate-deep inspiration with the ABC system.
After supine positioning and optimal immobilization of the patients using a breast board, CT-simulations with free breathing (FB) and ABC-mDIBH were performed at the CT-simulator (GE Lightspeed RT, GE Healthcare, Chalfont St. Giles, UK) in our department. Two sets of images were acquired with FB and ABC-mDIBH for all patients using a slice thickness of 3.75 to 5 mm. The FB scan was used for dosimetric comparison purposes and also served as a substitute in case of impaired patient compliance due to infections, etc., Radiation treatment planning (RTP) for actual treatment was based on CT-simulation images acquired at mDIBH.
For each patient, clinical target volume (CTV) contouring was performed in accordance with the European Society for Radiotherapy and Oncology (ESTRO) guidelines. The planning target volume (PTV) was generated by adding a 5 mm margin to the CTV, but PTV was cropped up to 5 mm from the surface of the skin. All patients had surgical clips in the tumor bed, and CTV boost was obtained with an isotropic expansion of surgical clips by 1 cm clipping the volume 3 mm inside skin profile or at chest wall. PTV boost was obtained with an isotropic expansion of CTV boost clipping the volume 3 mm inside skin profile and not allowing for more than 4 mm inside lung. Right lung, left lung, whole lung, liver, heart, and contralateral breast were delineated as organs-at-risk (OARs). The same physician performed delineation of target volume and OARs on the two image sets of each patient (with FB and ABC-mDIBH) using Advantage-Sim MD simulation and localization software (Advantage-Sim MD, GE, UK) to prevent interobserver variability. The same physicist was involved in generation of two different RT plans (FB and mDIBH) for each patient using identical beam organization and target coverage with PrecisePLAN (Elekta, UK) Treatment Planning System.
All treatments were delivered at the linear accelerator (LINAC) (Synergy, Elekta, UK) at our department with image guidance for online set-up verification by use of Electronic Portal Imaging Device (EPID) (Iview, Elekta, UK) and kilo-Voltage Cone Beam Computed Tomography (kV-CBCT) (X-ray Volumetric Imaging (XVI), Elekta, UK). All patients received field-in-field intensity modulated radiation therapy (FIF-IMRT) with incorporation of ABC-mDIBH. After WBI to a dose of 50 Gy with daily fractions of 2 Gy was delivered over 5 weeks, a sequential boost dose of 10 Gy was delivered in five daily fractions of 2 Gy for all patients.
Dose–volume histograms (DVHs) acquired from two RT plannings of each patient were used in comparative assessment of dose–volume parameters in both plans, with and without ABC-mDIBH. Assessed dose–volume parameters included volume receiving ≥20 Gy (V20), lung volume and mean lung dose (MLD) for the lungs, volume receiving ≥5 Gy (V5), V20, lung volume and MLD for the right lung, V5 and mean heart dose (MHD) for the heart, volume receiving ≥10 Gy (V10), volume receiving ≥30 Gy (V30), mean liver dose, liver volume which received 50% of the prescribed dose and volume of liver within the treatment field for the liver. Mann–Whitney U test was used for comparison of dose–volume parameters. Statistical analysis was performed using Statistical Package for the Social Sciences, version 15.0 (SPSS, Inc., Chicago, IL) software with the level of significance set at P < 0.05.
| » Results|| |
The median age was 47 years (range: 41-57 years), median duration of mDIBH was 24.4 seconds, and the median threshold for mDIBH was 1.8 liters. 20 patients (55.6%) had stage I and 16 patients (44.4%) had stage IIA breast cancer. Reproducibility of setup has been secured by use of periodical image guidance with Electronic Portal Imaging Device (EPID) (Iview, Elekta, UK) or kilo-Voltage Cone Beam Computed Tomography (kV-CBCT) (X-ray Volumetric Imaging (XVI), Elekta, UK) before treatment fractions, and all patients completed RT with ABC-mDIBH as planned. Total volume of the lungs was 2349 cc (range 1576 to 3213 cc) with FB and 3892 cc (2712 to 4890 cc) with ABC-mDIBH. While the mean increase in total volume of the lungs with ABC-mDIBH was 1543 cc (37% mean increase), mean increase in lung V20 was 107 cc (27% mean increase) which is in favor of lung V20 (p < 0.001). Mean reduction in V20 was 4.1% for lungs and 6.1% for ipsilateral lung (p < 0.001).
MLD decreased from 7 Gy to 5.2 Gy (26% reduction) for the total lung (p < 0.001) with a difference larger than 1.0 Gy for 29 patients. There was no difference ≥3.0 Gy for total lung MLD. For the ipsilateral lung, MLD decreased from 12.6 to 9.4 Gy (25% reduction) with a difference larger than 2.0 Gy for 27 patients (p < 0.001). Mean dose decreased from 1.7 Gy to 1.4 Gy (16% reduction) for the heart (p < 0.001). For right-sided breast cancer patients, the heart doses are usually low as expected. The difference in heart doses is very low with the differences below 0.5 Gy for 34 patients. Mean dose decreased from 4.6 Gy to 1.7 Gy (58% reduction) for liver (p < 0.001). Mean reduction in the liver volume which received 50% of the prescribed dose was 56 cc (p < 0.001). The difference above 5.0 Gy was observed in nine patients. Dose–volume parameters of the both lungs, right lung, heart, and liver acquired from the dose–volume histograms of the two plans with and without ABC-mDIBH are shown in [Table 2]. [Figure 1] shows axial planning CT images of a patient with ABC-mDIBH and FB.
|Figure 1:Axial planning CT images of a patient with ABC-mDIBH (a) and FB (b)|
Click here to view
| » Discussion|| |
Dosimetric results in our study based on comparative analysis of dose–volume parameters acquired from RT plans with FB and ABC-mDIBH revealed a statistically significant reduction in critical organ doses with incorporation of ABC-mDIBH [Table 2]. In the present study, MLD decrease was 1.8 Gy (26% reduction) for the total lung and 3.2 Gy for the ipsilateral lung (25% reduction). Mean reduction in V20 was 4.1% for lungs and 6.1% for in ipsilateral lung (p < 0.001). In the study by Essers et al, MLD reduction was very small (0.5 Gy) in the local breast radiotherapy. In the previous studies, ipsilateral lung V20 reductions were reported between 1.7% and 5.2% in breast cancer radiotherapy and lung V20 Gy has been shown to be an important predictive parameter for pulmonary toxicity in breast cancer radiotherapy.,,,,,,
There is little information relationship between pulmonary dose reduction and pulmonary side effects.,,,, Reduction in lung doses may decrease pulmonary toxicity, such as radiation pneumonia, pulmonary fibrosis and secondary lung cancer. Lind et al. reported the incidence of pneumonia as 0.9% in locally treated breast cancer and 4.1% in locoregional radiotherapy. Korreman et al. reported the rate of pneumonia probability as 28.1% for FB and 4.3% for DIBH. In the study by Smith et al., the incidence of 5-year pneumonia was reported as 0.72% in whole breast radiotherapy. Also, elimination of exposure of a given critical organ (lung, liver etc.) may lead to elimination of any risk for radiation induced secondary cancers. In a meta-analysis, increased risk of lung, esophageal cancer, and sarcoma were reported after breast cancer radiotherapy. Grantzau et al. reported that the median time between diagnosis of lung cancer secondary to breast cancer treatment was 12 years (range 1–26 years) and the risk of lung cancer increased by 8.5% per Gy delivered to the lung. Although the risk of lung cancer is relatively low (0.8%), the number of long-term survivors after breast cancer treatment is increasing, emphasizing the importance of the need for radiotherapy techniques that protect normal tissues.
In the previous studies, DIBH has been reported to reduce cardiac doses in left breast cancer radiotherapy, but the effect of DIBH on cardiac dose varies in right breast cancer radiotherapy.,,,,, In the study by Pedersen et al., the median heart volume receiving >50% of the prescription dose was reduced from 8% for FB to 1% for DIBH but there was no meaningful change or slight difference in other studies.,,
In our study, mean dose reduced from 1.7 Gy to 1.4 Gy (16% decrease) for the heart (p < 0.001). For right-sided breast cancer patients, the heart doses are usually low as expected. The difference in heart doses are very low with the differences below 0.5 Gy for 34 patients in our study. The importance of limiting cardiac doses has been reported in many studies.,, In the study by Darby et al., rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per Gy. SEER data showed that the risk of cardiac events is reduced by modern techniques. Small decreases in cardiac doses may have long-term benefits.
In right-sided breast cancer radiotherapy, liver doses are expected to be higher than left-sided breast cancer radiotherapy because liver and right breast are adjacent organs. With deep inspiration, liver moves away from the breast. There is little data on radiation-associated liver toxicity in breast cancer radiotherapy. In the study by Prabhakar et al., with analysis of only four patients, an average of 50% reduction in the dose of the liver with DIBH was reported. Conway et al. showed that an average of 42 cc reduction in the liver volume which received 50% of the prescribed dose. In our study, mean dose decreased from 4.6 Gy to 1.7 Gy (58% reduction) for liver (p < 0.001). The difference above 5.0 Gy was observed in nine patients. The volume of liver within the target volume decreased by 77% to 57.7 cc and mean reduction in the liver volume which received 50% of the prescribed dose was 56 cc. In the literature, if a mean dose of 30–32 Gy is applied to the liver, there is a risk of 5% radiation-induced liver disease (RILD) and the risk of RILD increases to 50% if the mean dose is 42 Gy. These doses administered to the partial liver do not have clinical significance for RILD development, but irradiation of the liver with FB is undesirable in patients with this excellent prognosis. As per the ALARA principle, reducing the exposure of normal tissues may have several benefits. It is not clear that a decrease in irradiated liver volume will reduce treatment-related side effects but may be important in patients with poor hepatic functional reserve. In addition, functional and radiographic changes in liver have been reported to be common with incidental irradiation.
Absence of clinical follow up to comment on treatment outcomes of the patients is an important limitation of this study which precludes assessing the clinical benefit of improved critical organ sparing with the ABC technique. Nevertheless, our dosimetric results which revealed improved critical organ sparing by use of ABC-mDIBH in this study may add to the current literature given the limited available data on the utility of breathing adapted RT with ABC-mDIBH for right-sided ESBC patients. With a relatively larger sample size, our study reports dosimetric results of a homogeneous patient group with right-sided ESBC receiving breathing adapted RT using the ABC technique. Reduced critical organ doses by incorporation of ABC-mDIBH may potentially translate into improved toxicity profile, and may allow for dose escalation particularly in the setting of focused RT delivery. Minimizing normal tissue exposure without comprimising target volume coverage is an excellent goal of RT in the millenium era to improve quality-of-life of cancer patients, and incorporation of ABC-mDIBH may potentially offer a viable strategy to achieve this goal for right-sided ESBC patients.
| » Conclusion|| |
Our study revealed that incorporation of ABC-mDIBH into adjuvant RT of right-sided ESBC patients results in significantly improved critical organ sparing. This viable strategy may be used to improve the toxicity profile of RT delivery but studies with long-term follow-up are warranted to assess clinical translations of improved critical organ sparing with ABC-mDIBH.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| » References|| |
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2018;68:7-30.
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev 2017;26:444-57.
Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009;33:315-8.
Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomised trials. N
Engl J Med 1995;333:1444-55.
Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220-9.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al.
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087-106.
Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al.
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3. non-inferiority trial. Lancet 2017;390:1048-60.
Corica T, Nowak AK, Saunders CM, Bulsara M, Taylor M, Vaidya JS, et al.
Cosmesis and breast-related quality of life outcomes after ıntraoperative radiation therapy for early breast cancer: A substudy of the TARGIT-A trial. Int J Radiat Oncol Biol Phys 2016;96:55-64.
Sager O, Dincoglan F, Uysal B, Demiral S, Gamsiz H, Elcim Y, et al.
Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma. Jpn J Radiol 2018;36:401-6.
Sager O, Beyzadeoglu M, Dincoglan F, Oysul K, Kahya YE, Gamsiz H, et al.
The role of active breathing control-moderate deep ınspiration breath-hold (ABC-mDIBH) usage in non-mastectomized left-sided breast cancer radiotherapy: A dosimetric evaluation. UHOD 2012;22:147-55.
Dincoglan F, Beyzadeoglu M, Sager O, Oysul K, Kahya YE, Gamsiz H, et al.
Dosimetric evaluation of critical organs at risk in mastectomized left-sided breast cancer radiotherapy using breath-hold technique. Tumori 2013;99:76-82.
Remouchamps VM, Vicini FA, Sharpe MB, Kestin LL, Martinez A, Wong JW. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys 2003;55:392-406.
Eldredge-Hindy H, Lockamy V, Crawford A, Nettleton V, Werner-Wasik M, Siglin J, et al.
Active Breathing coordinator reduces radiation dose to the heart and preserves local control in patients with left breast cancer: Report of a prospective trial. Pract Radiat Oncol 2015;5:4-10.
Kunheri B, Kotne S, Nair SS, Makuny D. A dosimetric analysis of cardiac dose with or without active breath coordinator moderate deepinspiratory breath hold in left sided breast cancer radiotherapy. J Cancer Res Ther 2017;13:56-61.
Krauss DJ, Kestin LL, Raff G, Yan D, Wong J, Gentry R, et al.
MRI-based volumetric assessment of cardiac anatomy and dose reduction via active breathing control during irradiation for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2005;61:1243-50.
Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol 2013;106:28-32.
Mast ME, van Kempen-Harteveld L, Heijenbrok MW, Kalidien Y, Rozema H, Jansen WP, et al.
Left-sided breast cancer radiotherapy with and without breath-hold: Does IMRT reduce the cardiac dose even further? Radiother Oncol 2013;108:248-53.
Chi F, Wu S, Zhou J, Li F, Sun J, Lin Q, et al.
Dosimetric comparison of moderate deep inspiration breath-hold and free-breathing intensity-modulated radiotherapy for left-sided breast cancer. Cancer Radiother 2015;19:180-6.
Swanson T, Grills I, Ye H, Entwistle A, Teahan M, Letts N, et al.
Six-year experience routinely utilizing moderate deep ınspiration breath-hold (mDIBH) for the reduction of cardiac dose in left-sided breast ırradiation for patients with early stage or locally advanced breast cancer. Am J Clin Oncol 2013;36:24-30.
Osman SO, Hol S, Poortmans PM, Essers M. Volumetric modulated arc therapy and breath-hold in image-guided locoregional left-sided breast irradiation. Radiother Oncol 2014;112:17-22.
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, et al.
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 2015;114:3-10.
Essers M, Poortmans PM, Verschueren K, Hol S, Cobben DC. Should breathing adapted radiotherapy also be applied for right-sided breast irradiation? Acta Oncol 2016;55:460-5.
Conway JL, Conroy L, Harper L, Scheifele M, Li H, Smith WL, et al.
Deep inspiration breath-hold produces a clinically meaningful reduction in ipsilateral lung dose during locoregional radiation therapy for some women with right-sided breast cancer. Pract Radiat Oncol 2017;7:147-53.
Prabhakar R, Tharmar G, Julka PK, Rath GK, Joshi RC, Bansal AK, et al.
Impact of different breathing conditions on the dose to surrounding normal structures in tangential field breast radiotherapy. J Med Phys 2007;32:24-8.
] [Full text]
Lind PA, Wennberg B, Gagliardi G, Rosfors S, Blom-Goldman U, Lideståhl A, et al.
ROC curves and evaluation of radiationinduced pulmonary toxicity in breast cancer. Int J Radiat Oncol Biol Phys 2006;64:765-70.
Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D, et al.
Technical factors associated with radiation pneumonitis after local±regional radiation therapy for breast cancer. Int J Radiat Oncol 2002;52:137-43.
Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih YC, et al.
Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 2012;307:1827-37.
De Ruysscher D, Sharifi H, Defraene G, Kerns SL, Christiaens M, De Ruyck K, et al.
Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics. Acta Oncol 2013;52:1405-10.
Lind PA, Rosfors S, Wennberg B, Glas U, Bevegard S, Fornander T. Pulmonary function following adjuvant chemotherapy and radiotherapy for breast cancer and the issue of three-dimensional treatment planning. Radiother Oncol 1998;49:245-54.
Korreman SS, Pedersen AN, Aarup LR, Nottrup TJ, Specht L, Nystrom H. Reduction of cardiac and pulmonary complication probabilities after breathing adapted radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys 2006;65:1375-80.
Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: A systematic review and meta-analysis of 762,468 patients. Radiother Oncol 2015;114:56-65.
Grantzau T, Thomsen MS, Væth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother Oncol 2014;111:366-73.
Conroy L, Yeung R, Watt E, Quirk S, Long K, Hudson A, et al.
Evaluation of target and cardiac position during visually monitored deep inspiration breathhold for breast radiotherapy. J Appl Clin Med Phys 2016;17:25-36.
Yeung R, Conroy L, Long K, Walrath D, Li H, Smith W, et al.
Cardiac dose reduction with deep inspiration breath hold for left-sided breast cancer radiotherapy patients with and without regional nodal irradiation. Radiat Oncol 2015;10:200.
Korreman SS, Pedersen AN, Nøttrup TJ, Specht L, Nyström H. Breathing adapted radiotherapy for breast cancer: Comparison of free breathing gating with the breath-hold technique. Radiother Oncol 2005;76:311-8.
Pedersen AN, Korreman S, Nyström H, Specht L. Breathing adapted radiotherapy of breast cancer: Reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. Radiother Oncol 2004;72:53-60.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al.
Risk of ischemic heart disease in women after radiotherapy for breast cancer. N
Engl J Med 2013;368:987-98.
Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 2013;108:179-82.
Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al.
Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:70-6.
Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al.
Quantitative analysis of normal tissue effects in the clinic: Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010;76:94-100.
[Table 1], [Table 2]